Medicine Overview

Adult Dose

Clinical InformationAdministration Information
Indication: Acute Renal Graft Rejection
Condition: Treatment
Dose: intravenous infusion – 1.5 mg/kg
Frequency: once daily
Duration: 7-14 days
Note: Indicated for the treatment of acute rejection in patients receiving a kidney transplant in conjunction with concomitant immunosuppression
Indication: Acute Renal Graft Rejection
Condition: Prophylaxis
Dose: intravenous infusion – 1.5 mg/kg
Frequency: once daily
Duration: 4-7 days
Note: First dose initiated prior to reperfusion of the donor kidney; indicated for the prophylaxis of acute rejection in patients receiving a kidney transplant in conjunction with concomitant immunosuppression

Child Dose

Clinical InformationAdministration Information
Indication: Prophylaxis and treatment of acute rejection in kidney transplant recipients
Dose: Intravenous – 1.5 mg/kg
Frequency: Daily
Duration: 4 to 7 days (prophylaxis) or 7 to 14 days (treatment)
Indication: Moderate to severe aplastic anemia in patients unsuitable for bone marrow transplantation
Age: 2 years and older
Dose: Intravenous – 10 mg/kg to 20 mg/kg
Frequency: Daily
Duration: 8 to 14 days; additional alternate-day therapy up to a total of 21 doses may be given
Administration

For intravenous use only, anti-human T-lymphocyte immunoglobulin (rabbit) must be reconstituted with sterile water and then further diluted in 0.9% sodium chloride or 5% glucose to a concentration typically between 1 mg/mL and 4 mg/mL. The solution should be gently swirled and allowed to reach room temperature before administration through a high-flow central vein using an in-line filter. The first dose is infused over at least 6 hours, while subsequent doses require at least 4 hours. Premedication with corticosteroids, antihistamines, and antipyretics is recommended to reduce infusion-related reactions. Dosage should be halved if white blood cell counts fall between 2,000-3,000 cells/mm3 or platelets between 50,000-75,000 cells/mm3, and discontinuation considered if counts drop further. Monitoring for anaphylaxis is required during and for 24 hours post-infusion.

Side Effect

Drug Interaction

Details coming soon

Disease Interaction

Details coming soon

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.